Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO vs rhIL-11 for Thrombocytopenia in Recurrent CRC
NCT03823079Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Feb 2019
- Primary completion
- Sep 2019
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, randomised, open-label trial of recombinant human thrombopoietin in Thrombocytopenia (2 arms), sponsored by Fudan University. Primary endpoints: Rate of recovery of platelet accounts up to 6 months and Duration after returning to normal up to 6 months. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT03823079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823079.